Pieris Pharmaceuticals EBITDA 2011-2026 | PIRS

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Pieris Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-38.6 M	-14.1 M	-11.9 M	-40.7 M	-49.4 M	-31.6 M	-26.1 M	-30.3 M	-14.2 M	-22.4 M	-13.4 M	-15.7 K	-274	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-274	-49.4 M	-22.5 M

Quarterly EBITDA Pieris Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-1.79 M	-	-	-	-14.9 M	-	-9.97 M	-12.3 M	-7.46 M	-	-17.2 M	-16.8 M	-5.06 M	-	-13 M	-4.66 M	-3.52 M	-	-2.55 M	-12 M	-10.5 M	-	-7.4 M	-1.97 M	-8 M	-	-4.92 M	-7.68 M	-7.91 M	-	-6 M	-5.71 M	-4.29 M	-	-3.65 M	-3.38 M	-3.62 M	-	-1.56 M	-2.58 M	81.6 K	-2.2 K	-5.76 K	-7.96 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
81.6 K	-17.2 M	-6.26 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	-37.8 M	$ 4.5	0.45 %	$ 862 M	Canada
ADC Therapeutics SA ADCT	-262 M	$ 3.83	1.32 %	$ 105 M	Schweiz
Agenus AGEN	-10.2 M	$ 3.64	9.31 %	$ 108 M	USA
Agios Pharmaceuticals AGIO	-467 M	$ 35.08	-0.36 %	$ 2.03 B	USA
Akebia Therapeutics AKBA	24.8 M	$ 1.39	0.36 %	$ 357 M	USA
Akari Therapeutics, Plc AKTX	-21.6 M	$ 3.95	-11.63 %	$ 266 B	Britain
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Aldeyra Therapeutics ALDX	-35 M	$ 1.57	-5.42 %	$ 94.3 M	USA
Aligos Therapeutics ALGS	-87.1 M	$ 8.08	1.38 %	$ 79.9 M	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Alnylam Pharmaceuticals ALNY	557 M	$ 331.14	3.85 %	$ 43.4 B	USA
Altimmune ALT	-94.4 M	$ 3.4	1.8 %	$ 300 M	USA
ALX Oncology Holdings ALXO	-103 M	$ 1.99	0.81 %	$ 107 M	USA
Amgen AMGN	14.2 B	$ 344.03	-1.12 %	$ 185 B	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Amneal Pharmaceuticals AMRX	451 M	$ 12.27	-1.68 %	$ 3.85 B	USA
Anika Therapeutics ANIK	-81.2 M	$ 14.99	1.28 %	$ 220 M	USA
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
ANI Pharmaceuticals ANIP	68.3 M	$ 73.8	-0.55 %	$ 1.43 B	USA
Annexon ANNX	-214 M	$ 5.56	1.0 %	$ 862 M	USA
Annovis Bio ANVS	-29.7 M	$ 2.56	12.28 %	$ 52.6 M	USA
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Aptorum Group Limited APM	1.19 M	$ 0.88	-5.16 %	$ 4.8 M	China
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Aprea Therapeutics APRE	-13.2 M	$ 0.7	-1.87 %	$ 4.58 M	USA
Aquestive Therapeutics AQST	-70.5 M	$ 4.12	-0.24 %	$ 441 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-23.9 M	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	-55.6 M	-	1.93 %	$ 17.4 M	USA
Arcturus Therapeutics Holdings ARCT	-73.2 M	$ 8.14	1.31 %	$ 223 M	Israel
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Ardelyx ARDX	-37.9 M	$ 5.99	0.84 %	$ 1.44 B	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
argenx SE ARGX	-349 M	$ 749.99	0.48 %	$ 25 B	Niderland
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Arcutis Biotherapeutics ARQT	-11.5 M	$ 24.06	1.82 %	$ 3.06 B	USA
Arvinas ARVN	-116 M	$ 10.87	0.14 %	$ 771 M	USA
Arrowhead Pharmaceuticals ARWR	121 M	$ 60.28	-1.23 %	$ 8.06 B	USA
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA
Assembly Biosciences ASMB	-12 M	$ 29.51	1.72 %	$ 331 M	USA
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	-50.6 M	-	10.36 %	$ 9.8 M	USA
Alterity Therapeutics Limited ATHE	-17.3 M	$ 3.62	1.82 %	$ 8.71 B	Australia